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Background
Human bone marrow and umbilical cord blood are sources of allogeneic hematopoietic stem
cells for transplantation, which is a life-saving treatment in a variety of diseases but is burdened
by delayed T-cell reconstitution. Observational studies evaluating T-cell reconstitution in post-
transplant recipients suggest that cord blood hematopoietic stem cells have a more effective
capacity for T-cell reconstitution. This study focuses on the comparison of the capacity of cord
blood and bone marrow hematopoietic stem cells to generate T cells in vitro.
Design and Methods
Hematopoietic stem cells were cultured in OP9-delta-like-1 and OP9-green fluorescent protein
co-cultures to estimate T and myeloid generation capacity, respectively. Phenotypic markers of
T-lineage or myeloid differentiation were measured by flow cytometry and used to analyze
their kinetics as a function of culture time. Hematopoietic stem cells were labeled with car-
boxyfluorescein diacetate succinamidyl ester and analyzed after culture to track their pheno-
typic progression in consecutive generations. Mixed OP9-delta-like-1 co-cultures were done
with either carboxyfluorescein diacetate succinamidyl ester-labeled bone marrow and unla-
beled cord blood hematopoietic stem cells, or vice versa, to evaluate their mutual influence on
T-lineage differentiation. The T-cell potential of hematopoietic stem cells was addressed quan-
titatively by limiting dilution analysis.
Results
Bulk cultures showed faster and more extensive T-cell differentiation by cord blood hematopoi-
etic stem cells. Furthermore, the T-lymphoid differentiation capacity of cord blood and bone
marrow hematopoietic stem cells can be discriminated very early based on the coordinated
expression of CD34 and CD7. Mixing experiments with cord blood hematopoietic stem cells
and bone marrow hematopoietic stem cells showed that these differences are cell intrinsic.
Quantitative clonal analyses demonstrated that CD34+CD38-/lo hematopoietic stem cells from
cord blood contained a two-fold higher T-lineage generation capacity than CD34+CD38-/lo bone
marrow hematopoietic stem cells, whereas the myeloid differentiation was similar. 
Conclusions
Our data shows that cord blood hematopoietic stem cells have higher T-lymphoid differentia-
tion potential than bone marrow hematopoietic stem cells and that this property is cell
autonomous.
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Introduction
There are currently three possible sources for procuring
the hematopoietic stem cells (HSC) used for stem cell trans-
plantation1 These three different sources exhibit specific
characteristics. Bone marrow HSC are residents of the bone
marrow niche, whereas mobilized peripheral blood HSC
have been stimulated by growth factors and are no longer
influenced by bone marrow stromal cells. Cord blood HSC
not only share some characteristics of mobilized peripheral
blood HSC, as they are no longer influenced by the bone
marrow niche, but they also have characteristics deriving
from the young age of the donor. The ability of human HSC
to sustain long-term hematopoiesis in vitro was reported to
be higher for cord blood than for adult bone marrow, as
illustrated by differences in cloning efficiency for myeloid,
erythroid and mixed myeloid-erythroid colony-forming
cells.2 Interestingly, there was a gradual shift towards the
production of myeloid colony-forming cells upon culture;
the lymphoid potential was not investigated. It is, however,
of relevance to investigate whether these differences
between cord blood and bone marrow HSC also translate
into differences in T-cell potential, especially because, after
HSC transplantation, the recovery of T cells is delayed in
comparison to that of other lineages and this delay is a
major cause of life-threatening infections.3
T cells develop within the thymus after entry of circulat-
ing hematopoietic progenitor cells with uncertain pheno-
type. Recent evidence suggests that all T-lineage potential
resides within the most primitive CD34+CD38-Lin- subset
of cord blood and bone marrow precursors, although earlier
studies showed that the CD34+CD38+ subset also has T-lin-
eage capacity in vitro. The identity of the most immature
thymocytes remains unclear, but the latest evidence sug-
gests that the CD34+CD10+CD1a-CD7- subset4 contains the
most primitive intrathymic T-cell precursors. In any case, as
for murine T-cell differentiation, developing human T cells
follow a series of stage-specific differentiation events that
can be characterized by the coordinate expression of CD4
and CD8, whereby double-negative cells are the early pre-
cursor population, double-positive cells represent T cells
that undergo TCR-αβ selection and single CD4 and CD8
cells represent the end-stage of intrathymic post-selection
naïve T cells.5
Studies of stem cell activity in humans with T-cell lineage
capacity have long been hampered by the lack of robust and
reproducible in vitro T-cell differentiation assays. Using HSC
from fetal liver, we were able to obtain robust T-cell differ-
entiation in vitrowhen these cells were introduced into fetal
thymi from NOD-SCID mice and the fetal organs were cul-
tured in vitro.6 With this hybrid human-mouse fetal thymus
organ culture technique (FTOC), the kinetics of the very
early steps of T-cell differentiation could be addressed by
the sequential appearance of surface and intracellular anti-
gens, including CD4, CD7, HLA-DR and cytoplasmatic
CD3ε. We showed that the early CD34+CD38-CD4-CD7-
precursor cells do not express intracellular cytoplasmic CD3
(cyCD3) but display HLA-DR in varying intensities from
negative to strongly positive. These cells differentiate into a
CD4+ population that remains CD7-cyCD3-HLA-DR++ and
into a CD4- population that expresses CD7 and cyCD3.
The CD4+CD7-cyCD3- cells differentiate into phenotypical-
ly and functionally mature dendritic cells but do not differ-
entiate into T or NK cells. The CD4-CD7-cyCD3+ popula-
tion differentiates into a CD4+CD7+cyCD3+HLA-DR- popu-
lation, which has lost its potential to differentiate into den-
dritic cells, but is able to differentiate into NK cells and T-
cell receptor (TCR)-αβ and TCR-γδ T cells. With this hybrid
human-mouse FTOC, we7 and others8,9 were able to show
that human HSC from cord blood generate more T cells
than bone marrow HSC. However, the migration efficiency
of the HSC into the lobes of fetal thymus in this FTOC
assay is important and could be responsible for the
observed differences. Nowadays, in vitro development of
human HSC into T cells can be obtained by co-culture with
a murine bone marrow-derived OP9 stromal cell line engi-
neered to express the mouse DLL1 Notch ligand (OP9-
DL1).10
Here, we present a study in which we examined the dif-
ferences in myeloid and T-cell progenitor capacity between
cord blood and bone marrow HSC in more detail using the
OP9-DL1 co-culture system. 
Design and Methods
Cell samples
Samples from cord blood and adult bone marrow were obtained
and used according to the guidelines of the Medical Ethical
Commission of Ghent University Hospital (Ghent, Belgium), and
informed consent was obtained in accordance with the
Declaration of Helsinki.
Mononuclear cells were collected after centrifugation over
Lymphoprep and were cryopreserved in 10% dimethylsulfoxide,
90% fetal calf serum until required. Cells were thawed and the
CD34+ cells were selected using magnetic microbeads (Miltenyi
Biotec). Cells were then stained with CD34-APC, CD38-PE,
CD14-FITC, CD19-FITC, CD56-FITC (BD Biosciences) and sorted
for CD34+38-lin- (cord blood and bone marrow) to a purity of
greater than 99% using a FACSAria II cell sorter (BD Biosciences). 
Carboxyfluorescein diacetate succinamidyl ester labeling 
For carboxyfluorescein diacetate succinamidyl ester (CFSE)
labeling,9,11 cord blood or bone marrow CD34+cells were resus-
pended at a density of 1¥106/mL in phosphate-buffered saline with
0.1% bovine serum albumin containing 5 mM CFSE (Molecular
Probes). After 4 min at 37°C, further uptake of the dye was
blocked by the addition of cold phosphate-buffered saline + 30%
fetal bovine serum. The cells were washed three times, with the
last wash being performed in serum-free phosphate-buffered
saline. Finally, the cells were resuspended at a density of 5¥105/mL
in α-MEM supplemented with 20% fetal calf serum, and
cytokines, stem cell factor, FMS-like tyrosine kinase-3 ligand
(FLT3L), and thrombopoietin (20, 10, 10 ng/mL, respectively) and
cultured overnight at 37°C in 24-well plates, to allow the efflux of
unbound CFSE.
OP9 co-cultures
OP9-GFP and OP9-DL1 cells were maintained in complete
medium.10 For limiting dilution experiments, monolayers of OP9
cells were established in 96-well plates or 48-well plates. Bulk cul-
tures were performed in 24-well plates (Falcon, Becton-Dickinson).
For CFSE experiments, CD34+ cells were cultured for 4 days in 24-
well plates with OP-DL1 cells in complete medium and cytokines:
SCF (50 ng/mL), FLT3L (20 ng/mL), and interleukin-7 (5 ng/mL).
Experiments were started with 20,000 cells/well. In mixing exper-
iments, 10,000 CFSE-labeled CD34+ cells from cord blood were
mixed with 10,000 unlabeled CD34+ cells from bone marrow or
vice versa. Some of the CFSE-labeled cells were cultured in the pres-
ence of 0.1 mg/mL colcemid as a control for undivided cells. For
T potency of cord blood and bone marrow stem cells
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long-term experiments, co-cultures were started with 4,000-5,000
CD34+ cells/well.
Phenotypic characterization
Cord blood or bone marrow HSC were stained with the follow-
ing antibodies: CD34-FITC, CD4-PE, CD15-PE, CD14-APC,
TCRαβ-PE or APC (Miltenyi, Biotec) CD1-PE, CD7-PE, CD8β
(Coulter) CD3-APC-Cy7, HLA-Dr-APC-Cy7, CD4-PE-Cy7, CD5-
PE-CY7, CD45-Percp-Cy5.5 5 (E-bioscience), CD34-APC, CD7-
V450, TCRγδ-FITC, CD14-FITC, CD19-FITC , CD56-FITC (BD).
CD1-FITC (clone OKT6) was cultured; antibody was purified and
labeled in our laboratory. Dead cells were excluded with propidi-
um iodide. Multicolor sorting was done with a FACSAria II
(Becton Dickinson). Multicolor analyses were done with an LSR II
flow cytometer equipped with an HTS plate reader system. FACS
data were analyzed using either FACSDIVA, FlowJo software (Tree
Star) or ModFit LT (Verity Software).
Cloning analysis of myeloid and T-cell lineage potential
Cord blood or bone marrow CD34+38-/lo cells from three differ-
ent individual samples each were sorted using the BD Clonecyt
Plus Option (BD Biosciences) to deposit 1, 3, 10 or 30 cells (with
30-48 replicates for each donor) directly into individual wells of a
96-well plate containing OP9-DL1 or OP9-GFP cell monolayers
and complete medium with the appropriate cytokines.12 Each
week cells were transferred to fresh OP9-DL1 or OP9-GFP mono-
layers in 96-well plates: half of the medium was removed and the
complete wells were resuspended and transferred to fresh mono-
layers and supplied with fresh medium and cytokines. The last
week, the cells were transferred to 48-well plates containing OP9-
DL1 or OP9-GFP monolayers. Cells in co-cultures on OP9-GFP
were analyzed after 19-21 days of co-culture, whereas cells in co-
culture on OP9-DL1 cells were analyzed after 28-32 days of co-cul-
ture.
Statistical analysis
Data from the limiting dilution assays of each cell source were
pooled for statistical analysis using ELDA software
(http://bioinf.wehi.edu.au/software/limdil13).
Results
Higher frequency of hematopoietic stem cells with 
T-cell potential in cord blood than in bone marrow
hematopoietic stem cells
To determine the T-lineage potential of bone marrow
and cord blood HSC, limiting dilution assays were per-
formed using OP9-DL1 co-culture assays. Graded num-
bers of CD34+CD38-Lin- HSC from bone marrow and cord
blood were co-cultured with OP9-DL1 stromal cells, and
assayed phenotypically after 4-5 weeks for the presence of
the following populations: undifferentiated CD34+CD7-
HSC, CD4+HLA-DR+ dendritic cells and two populations
engaged in two successive steps along the T-lymphoid
pathway: uncommitted CD5+CD7+ CD4-CD1- early T-cell
precursors and CD5+CD7+ CD1+CD4+ cells, which repre-
sent a further stage of committed T-cell progenitors.5,14 As
shown in Table 1, the frequency of HSC that have the
potential to differentiate into CD34+CD7- cells was higher
in cord blood than in bone marrow. There were no signif-
icant differences between bone marrow and cord blood
HSC regarding the frequency of generation of CD4+HLA-
DR+ dendritic cells. Importantly, the frequency was two
times higher in cord blood than in bone marrow HSC
when the potential to differentiate into CD5+CD7+ early T
cells was evaluated, and this increased to a 3-fold differ-
ence when CD5+CD7+CD1+CD4+ committed T-lineage
precursors were scored at a later stage of differentiation. 
In parallel, limiting dilution assays were performed to
compare the myeloid differentiation capacity of bone mar-
row and cord blood HSC. OP9-GFP co-culture assays were
used for this purpose as they are better suited for the
analysis of myeloid development due to the absence of T-
lineage-inducing Notch ligands. Graded numbers of
CD34+CD38-Lin- HSC from bone marrow and cord blood
were co-cultured with OP9-GFP stromal cells and were
phenotypically assayed after 2-3 weeks for the presence of
the following populations: undifferentiated CD34+ HSC,
CD14+HLA-DR+ monocytes and CD15+ granulocytes. As
shown in Table 2, the frequency of bone marrow HSC and
cord blood HSC differentiating into CD34+ HSC and
CD14+ HLA-DR+ monocytes did not differ significantly.
However, the potential to develop into CD15+ granulo-
cytes was higher in cord blood HSC than in bone marrow
HSC.
Thus, while little difference was observed with respect
to the myeloid differentiation capacities of bone marrow
and cord blood HSC, it is clear that the T-lineage potential
of bone marrow-derived HSC is dramatically reduced
compared to that of cord blood HSC.
Faster and more extensive T-cell differentiation by cord
blood hematopoietic stem cells
Given this reduction in T-lineage potential in adult bone
marrow HSC compared to cord blood HSC, we decided to
investigate this difference further using bulk culture assays
as they provide more cells for detailed and kinetic analyses.
As shown in Figure 1, a quantitative analysis revealed that
cord blood HSC generate more cells in OP9-DL1 co-culture
in comparison with bone marrow HSC. 
However, a difference in cellular expansion was not suf-
ficient to explain the difference in T-lineage output between
the two HSC sources since the frequencies of the develop-
ing T-cell subsets were also increased in cultures initiated
M. De Smedt et al.
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Table 1. Comparative frequency analysis of lineage potential in human hematopoietic stem cells from cord blood (CB) and bone marrow (BM)
co-cultured in OP9-DL1 cells.
                                                                                          Lineage potential frequency-1 (95% confidence limits)
HSC Stem cells P Dendritic cells P Early precursor T cells P Post commitment T cells P
source* CD34+CD7- CD4+HLA-DR+ CD5+CD7+ CD4-CD1- CD7+CD5+CD1+CD4+
CB 3.26 (2.88-3.72) 1.61 10-5 5.81 (5.07-6.69) NS 1.81 (1.63-2.02) 8.33 10-18 2.56 (2.27-2.90) 3.54 10-35
BM 4.91 (4.29-5.63) 5.24 (4.57-6.02) 3.74(3.28-4.27) 8.06(6.98-9.32)
*CD34+CD38lo/- HSC were sorted at limiting numbers in wells of a 96-well plate containing OP9-DL1 cells and co-cultured for 28-35 days before harvesting for flow cytometric analy-
sis. Individual wells were scored for the presence of different cell types based on staining as indicated. Statistical analysis was performed using the ELDA software.13
with cord blood HSC compared to those started with bone
marrow HSC (Figure 2). 
After 10 days, analysis of CD34 versus CD7 showed that
cord blood HSC generated cells with a CD34+CD7+ pheno-
type more efficiently than did bone marrow HSC. In con-
trast, bone marrow HSC generated a higher frequency of
cells with a CD34-CD7- phenotype in comparison with cord
blood HSC. When the populations were analyzed on day
20 according to the coordinate expression of CD4 and CD7,
we observed that cells co-expressing CD4 and CD7 were
clearly present in the OP9-DL1 co-cultures with HSC from
cord blood, but this was not the case for the co-cultures
started with bone marrow HSC. In these latter cultures,
almost none of the CD4 cells expressed CD7 and could be
regarded as precursors of CD4+HLA-DR+ monocytic/den-
T potency of cord blood and bone marrow stem cells
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Table 2. Comparative frequency analysis of lineage potential in human hematopoietic stem cells from cord blood (CB) and bone marrow (BM)
co-cultured in OP9-GFP cells.
Lineage potential frequency-1 (95% confidence limits)
HSC source* Stem cell P Granulocyte P Monocyte P
CD34+ CD14-CD15+ CD14+HLA-DR+
CB 3.56 (3.13-4.06) NS 1.43 (1.32-1.58) 0.00151 1.35 (1.25-1.48) NS
BM 3.06 (2.70-3.49) 1.78 (1.61-1.99) 1.31 (1.22-1.43)
*CD34+CD38lo/- HSC were sorted at limiting numbers in wells of a 96-well plate containing OP9 cells and co-cultured for 21 days before harvesting for flow cytometric analysis.
Individual wells were scored for the presence of different cell types based on staining as indicated. Statistical analysis was performed using the ELDA software.13
Figure 1. Higher total
nucleated cell expan-
sion by cord blood (CB)
HSC. HSC cells were
co-cultured with OP9-
DL1 cells. After incu-
bation during the indi-
cated time period,
cells were harvested
and total nucleated
cell number was ana-
lyzed. Individual data
are represented as
closed circles (CB) or
open circles (BM) with
mean (black solid line)
± SEM (dashed line).
Figure 2. Faster and more extensive T-cell differentiation by cord blood (CB) HSC. Sorted CD34+CD38-Lin- HSC from CB and bone marrow
(BM) were cultured on OP9-DL1 cells in the presence of interleukin-7, Flt3 ligand and stem cell factor, and their developmental progression
was assessed at the indicated time points by flow cytometric analysis for different antigens as indicated. Numbers in quadrants indicate the
percentage of cells. TCR-αβ and TCR-γδ (CD3+-αβ cells) are delineated by regions, figures next to those regions indicate the corresponding
percentage of cells. 
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dritic population (Figure 2).
These experiments show that there were significant dif-
ferences between bone marrow and cord blood HSC in the
early steps of differentiation after a short period of co-cul-
ture in OP9-DL1 cells. 
After 30 days of culture, analysis of the coordinated
expression of CD4 and CD7 showed that HSC from bone
marrow are more efficient in generating a population that is
CD4+CD7-. This population also expresses HLA-DR (data
not shown). In contrast, the distinguishing feature of HSC
from cord blood is a predominance of CD7+ cells. Some of
these cells were CD4+ and represented cells that were
already CD4 immature or double-positive thymocytes. The
other part was CD4- and represented cells at earlier stages
of differentiation. We, therefore, may assume that after 30
days of culture the differences in T-cell generating capacity
between bone marrow (fewer double-positive, fewer CD7
cells) and cord blood are apparent.
After 6 weeks of co-culture with OP9-DL1 cells, cord
blood HSC did not only generate a higher number of cells
(Figure 1), but also higher frequencies of double-positive
thymocytes, TCR-αβ and TCR−γδ Τ cells (Figure 2). This
indicates that cord blood HSC are more efficient at T-cell
generation than bone marrow HSC. When we analyzed the
kinetics of the T lymphoid differentiation, we noted that
TCR-αβ and TCR-γδ T cells were already present after 30
days when the cultures were initiated with HSC from cord
blood, whereas these T cells were nearly absent in corre-
sponding bone marrow HSC cultures. After 30 days of co-
culture, HSC from cord blood had already generated a sig-
nificant number of double-positive thymocytes, whereas
this cell population was barely present when HSC from
bone marrow were used.
Collectively, the quantitative and qualitative data show
that HSC from cord blood have a more robust T-cell differ-
entiation capacity compared to HSC from bone marrow.
The T lymphoid differentiation capacity of cord blood 
and bone marrow hematopoietic stem cells can be 
discriminated very early in OP9-DL1 co-cultures
Given the differences in both proliferation and differenti-
ation between cord blood and adult bone marrow HSC
with respect to T-cell differentiation, we initiated CFSE
experiments in OP9-DL1 co-cultures to investigate the rela-
tionship between the two phenomena. The CD34high prog-
eny for both sources divided actively up to six or seven
times during a 4-day culture period (Figure 3A,B). The
CD34+ cell divisions were developmentally asymmetrical.
Most cells in the first to third generations retained the orig-
inal bright levels of CD34, typically found in human HSC
and consistent with self-renewal of CD34highLin− cells which
has been described in conditions of high Notch activation.15-
17 However, some of the cord blood CD34high progenitor cells
started a stepwise differentiation wave, from the first-sec-
ond generation onwards, in which they retained CD34high
expression but also up-regulated CD7 (Figure 3C). These
CD34high cells continued to divide but progressively down-
regulated CD34 from the third generation onward.
Importantly, bone marrow HSC did not up-regulate CD7 to
the same extent and instead up-regulated HLA-DR and sub-
sequently also CD4, thus differentiating towards the den-
dritic cell lineage, despite the presence of high densities of
the Notch ligand DLL1 (Figure 3C,D). This wave was more
prominent for bone marrow HSC than for cord blood HSC
and continued by most of the cells in the fourth to seventh
generations and completed in the sixth generation. 
Thus, these data show that in the first 4 days of culture,
CD34+Lin– progenitors can differentiate along two distinct
developmental pathways: one lymphoid and one myeloid.
In the lymphoid pathway CD34 expression is maintained
during more cell divisions and CD7 is up-regulated. Finally,
CD34 expression is down-regulated but CD7 expression is
maintained. Along the myeloid pathway, differentiation is
characterized by an immediate down-regulation of CD34
and absence of CD7 expression. Using the in vitro hybrid
human-mouse FTOC, we previously showed that, for
CD34+ progenitors from human fetal liver, these features
allow an early discrimination between CD34+CD7+ progen-
itor cells that will become lymphoid cells and CD34-CD7-
cells that will become dendritic/monocytic cells.6
Consistent with these data and the phenotypic changes
observed in the CFSE experiments, we used these parame-
ters to estimate the frequency of lymphoid and myeloid
progeny obtained from CD34+Lin– progenitors from bone
marrow and cord blood. As shown in Figure 4, CD34+Lin–
progenitors from bone marrow have a significantly higher
potential than those from cord blood to produce myeloid
cells (P=0.007), whereas the potential to produce lymphoid
cells is significantly higher for the cord blood progenitor
cells (P=0.006). 
Overall, these results show that adult bone marrow HSC
contain a large fraction of precursors that develop along the
myeloid pathway but not along the lymphoid T-lineage
pathway, despite the abundant presence of Delta-like
Notch ligands.
The difference in T-cell developmental potential 
of cord blood and bone marrow hematopoietic stem 
cells is cell-autonomous 
The superiority of cord blood HSC over bone marrow
HSC at engaging in the T-cell developmental pathway in
OP9-DL1 co-cultures could be due to non-cell-
autonomous phenomena, including differential produc-
tion of cytokines or other soluble factors, or the emer-
gence of a subpopulation of cells that negatively or posi-
tively influences differentiation into T cells. To address
this issue, we mixed HSC from cord blood and bone mar-
row and traced their progeny.
In a first series of control experiments, HSC from cord
blood or bone marrow were labeled with CFSE and cul-
tured in OP9-DL1 co-cultures for 4 days. When compared
to unlabeled cord blood or bone marrow cells, respective-
ly, the frequencies of the CD34- progenitors engaged in the
myeloid pathway, CD34+CD7+ progenitors engaged in the
lymphoid pathway and the number of CD34+CD7- pro-
genitors remained unchanged (Table 3), indicating that the
cell labeling procedure did not interfere with the cell
developmental properties in our co-culture assay. In addi-
tion, CFSE analysis demonstrated that the proliferation of
the CFSE-labeled cord blood or bone marrow cells was not
affected when mixed with unlabeled cord blood or bone
marrow cells (data not shown). Moreover, and in agreement
with our previous assay (Figure 3A), cells predominantly
maintained their original CD34+CD7- phenotype during
the first three generations, compatible with self-renewal.
Populations in further divisions (fourth and fifth) showed
an important proportion of CD34+CD7+ early lymphoid
and T-lineage precursors, while populations in the sixth
and seventh divisions predominantly contained cells with
a CD34- phenotype, indicative of cells engaged in a
M. De Smedt et al.
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myeloid pathway. Importantly, as shown in Figure 5 and
Table 3, when equal amounts of unlabeled bone marrow
HSC and CFSE-labeled cord blood HSC were mixed and
cultured on OP9-DL1 cells, the properties of the generated
cord blood cells did not change and were similar to those
of the OP9-DL1 control co-cultures initiated with only
cord blood HSC. As shown in Figure 5 and Table 3, similar
results were obtained when the properties of CFSE-
labeled bone marrow HSC in OP9-DL1 co-cultures were
analyzed in the presence of unlabeled cord blood HSC. In
conclusion, these results show that the reduced T-lineage
potential of adult bone marrow HSC is due to a cell-intrin-
sic defect that, furthermore, cannot be rescued by the
presence of developing early T-cell precursors from cord
blood.
Discussion
In this study we investigated the difference in T-lineage
capacity between cord blood and adult bone marrow HSC.
Clonal experiments revealed a significantly lower T-cell dif-
ferentiation potential for the bone marrow HSC compared
to the cord blood HSC and CFSE experiments in bulk cul-
tures showed that this was due to the preferential adoption
of a myeloid differentiation program by the early dividing
bone marrow HSC, despite the presence of abundant Notch
ligands. Furthermore, mixed cultures of cord blood and
adult bone marrow HSC revealed that this reduction in
early T-lineage priming in bone marrow HSC was cell-
intrinsic and not remedied by the presence of developing T
lymphocytes. 
T potency of cord blood and bone marrow stem cells
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Figure 3. Comparative CFSE profiles and cell surface phenotype of HSC co-cultured on OP9-DL1 for 4 days reveals higher propensity of cord
blood (CB) than bone marrow (BM) HSC to generate T lymphocytes. CFSEhighCD34highLin− precursors were purified by FACS (>99.5% pure, n =
3) from CB or BM mononuclear cells loaded with CFSE; labeled with CD34-, Lin-specific antibodies; and co-cultured on OP9-DL1 stroma for
4 days (D4). The CFSEhighCD34highLin− progeny was stained with CD34, CD7, CD5, CD4 and HLA-DR-specific antibodies and submitted to flow
cytometry analysis to quantify CFSE content (numbers on top of each peak designate the number of progeny divisions, with 0 representing
no division) (A) and surface CD34 levels in each generation dot-plot analysis of CD34 expression versus CFSE content (B), using the same
samples as in (A) [position of undivided cells is shown (↓)]. (C) Day 4 expression of CD34 and CD7 in gated CD34+ cells ordered by their
progeny generation, as defined by CFSE levels and indicated by numbers on top of the plot. Numbers in quadrants represent the frequency
of positive cells. (D) Day 4 expression of CD4 and HLA-DR in gated CD34+ cells ordered by their progeny generation, as defined by CFSE
levels and indicated by numbers on top of the plot. Numbers in quadrants represent the frequency of positive cells. Data are representative
of the results from three independent experiments. Note that in OP9-DL1 co-cultures, in the first wave of development, CD34highLin− precur-
sors asymmetrically self-renew and differentiate into two distinct populations that down-regulate CD34, up-regulate HLA-DR and acquire
CD4 on the one hand and maintain CD34, down-regulate HLA-DR but acquire CD5 and CD7 on the other hand.
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Through limiting dilution analysis on OP9-DL1 cells, we
determined the frequency of cord blood and bone marrow
HSC that had the potential to differentiate into T-cell pro-
genitors and found that this frequency was twice as high for
cord blood cells as compared to bone marrow cells. Our
data for cord blood HSC reveals a 3-fold higher progenitor
potential compared to the data obtained by Awong et al.18,
but this is most likely due to kinetic differences with respect
to timing of analysis since they looked after 11 days of cul-
ture, whereas we scored the cells after 28-35 days. This cul-
ture period allowed us to circumvent the issues of differ-
ences in developmental kinetics, because we have shown
previously19 that at that time bone marrow cells, although
they have slower kinetics, have already progressed to this
early step of T-lineage differentiation on OP9-DL1 cells.
The longer culture period may account for the higher
potential in our study since the cells were provided with
more time to expand. In a very recent study, Dick’s group 20
analyzed the clonal lineage potentials of a number of differ-
ent CD34+ hematopoietic progenitor subsets from both
cord blood and bone marrow. Since the CD34+CD38- HSC
population used in this study, was divided into four differ-
ent subsets in their study, it is difficult to compare the
results from both studies. Using CD34+CD38-/lo HSC, we
found a cloning efficiency of 47.9%±15.5 for cord blood
and 12.5%±7.2 for bone marrow. In their study, the most
robust fraction of CD34+CD38-/lo precursors that contained
T-lineage potential also revealed a higher efficiency for cord
blood HSC (45%) as compared to bone marrow HSC
(27%). Despite the different populations used, the results
from both studies are surprisingly similar and the relatively
small differences that are observed can easily be attributed
to the subsets that were investigated, as well as to differ-
ences in culture duration and phenotypic characterization.
In each case, from the study by Dick group’s, it is clear that
the total CD34+CD38-/lo subset comprises all main precur-
sors for T-lineage cells, indicating that our results are repre-
sentative for the global T-lineage potential of cord blood
and bone marrow HSC. 
Remarkably, while we observed a clear difference
between cord blood and bone marrow HSC with respect to
the generation of uncommitted T-lineage precursors, this
difference significantly increased when scoring a further
developmental stage along the T-lineage pathway, namely
committed T progenitors. Since bulk cultures suggest that
the HSC were given sufficient time to differentiate towards
this stage, this finding suggests that not only is early com-
mitment different between both HSC sources, but also that
other differences are present within the differentiating T-
lineage precursors. While this may involve differences in
proliferation capacities and cell survival, our results suggest
that the defect in T-lineage potential of bone marrow HSC
occurs at multiple stages of T-cell development and as a
result of different phenomena.
The difference between cord blood and bone marrow
HSCs in engagement along the T-lineage pathway was
revealed using bulk culture analysis in conjunction with
CFSE labeling. With this approach, we were able to track
the order of phenotypic changes towards the T cell and
myeloid pathway in the early steps of differentiation. Based
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Figure 4. Frequency of myeloid and lymphoid cells after 4 days of
co-culture of HSC from cord blood (CB) and bone marrow (BM) on
OP9-DL1. HSC from CB and BM were co-cultured for 4 days on OP9-
DL1 stromal cells and phenotyped for coordinated expression of
CD34 and CD7. Bars represent the frequencies of the cells generat-
ed by CB (black bars) or BM (white bars). Bars represent the mean
with the standard deviation of three independent experiments.
Figure 5. Mixing cord blood (CB) and bone marrow (BM) HSC does
not influence the intrinsic difference in T-cell developmental poten-
tial. HSC were labeled with CFSE, cultured for 4 days on OP9-DL1
cells and subsequently harvested and stained with CD34 and CD7.
In panel (A), left histograms show the CFSE profile of total CB-CFSE
HSC alone (top row) or when cultured in the presence of unlabeled
BM HSC (bottom row). In panel (B), left histograms show CFSE pro-
files of total BM-CFSE HSC alone (top) or when cultured in the pres-
ence of unlabeled CB HSC (bottom row). The corresponding his-
tograms on the right show an overlay of the CFSE profiles on the
cells gated on the three phenotypes as indicated. As the profile of
the CFSE-labeled HSC does not change when they are cultured with
the HSC from the different sources, these data strongly suggest that
the differences in cell proliferation are cell autonomous. Data are
representative of two independent experiments shown in Table 3.
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on our previous studies6 with fetal liver HSC in FTOC and
cord blood HSC in OP9-DL1 co-cultures,21 the rapid upreg-
ulation of CD7 in CD34+ HSC at high levels can be used as
an early marker for engagement towards T-cell differentia-
tion. Since this process is Notch-dependent, the highly sig-
nificant difference between the abundance of CD34+CD7++
cells in the OP9-DL1 co-cultures initiated with cord blood
HSC and the near absence of this population when starting
with bone marrow HSC suggests that fewer bone marrow
HSC are responsive to the Notch ligand DL1. Since bone
marrow HSC, compared to their cord blood counterpart,
display a significantly higher frequency of CD34-CD7- cells
that represent myeloid lineage differentiation, our findings
indicate that very early in the developmental pathway, an
important bias for lymphoid cell development discriminates
cord blood from bone marrow HSC. Indeed, Delta-Like lig-
and induced Notch signaling has been shown to suppress
myeloid differentiation, a process that is critical to maintain
developing T cells along the T-lineage pathway. The idea of
lineage bias is also in accordance with the observation of
Panepucci et al.22 who showed that CD34+ and CD133+ cord
blood cells had higher HES1 transcript levels compared to
their bone marrow counterparts. This could indicate that
HSC may have already experienced Notch signaling before
migrating to the thymus, a process that may involve
Jagged1-mediated Notch signaling. In addition, the
observed increased transcript levels of Notch1, TAL1, dis-
tinct NF-κB subunits, and other transcription factors on cord
blood HSC may prompt these cells to respond more effec-
tively to signals driving lymphopoiesis. 
Given the bias of bone marrow HSC to develop along the
myeloid pathway, it was important to investigate whether
these or other cells that develop in parallel with the T-lin-
eage cells could negatively affect T-cell development, there-
by explaining the reduced T-cell potential of bone marrow
HSC compared to cord blood HSC. In order to investigate
whether HSC from both sources display cell intrinsic differ-
ences with respect to early T-cell development, we used
CFSE staining to trace the differentiation of HSC from bone
marrow and cord blood in mixing experiments. First, we
showed that the CFSE staining as such did not influence the
differentiation kinetics and characteristics of the HSC, and
in addition, that mixing CFSE-labeled cells with unlabeled
cells from the same source had no influence on these
parameters. Importantly, when either labeled cord blood or
bone marrow HSC were mixed with unlabeled bone mar-
row or cord blood, respectively, no effect was observed on
the generation of the different subsets according to the
coordinate expression of CD34 and CD7. We, therefore,
provide evidence that the differences in T-cell progenitor
frequency between cord blood and bone marrow HSC are
cell-autonomous and are not due to the production of lym-
phoid promoting factors by cord blood HSC or of lym-
phoid-inhibiting factors by soluble factor or bone marrow
HSC. These results also illustrate that early developing lym-
phocytes cannot positively influence other HSC to develop
along the T-lineage pathway.
Our finding is in line with new insights into the identifi-
cation and definition of HSC.23 Recently, it was shown, in
mice, that abundant CD150 expression identified a subset
of HSC with very potent self-renewal capacity. In addition,
CD150 levels predicted myeloid versus lymphoid reconsti-
tution potential with robust myeloid potential for CD150high
HSC and superior lymphoid reconstitution for CD150-
HSC.24 However, although this CD150high population had an
impressive capacity to reconstitute the lymphoid system,24-
27 it partially preserved self-renewal and did not express
FLT3. These cells are, therefore, different from the lym-
phoid-primed multipotent progenitors identified by
Jacobsen’s group.28 In addition, the population also retained
erythroid-megakaryocytic potential.24 These properties are
compatible with the view that stem cells may already show
propensity to generate preferentially different lineages.29
From our observations, we propose that HSC from cord
blood and bone marrow have different differentiation
capacities and that cord blood are more lymphocyte-lin-
eage-biased and bone marrow are more myeloid-lineage-
biased. It will be important to explore whether markers can
be found for human HSC that, analogous with CD150 in
mice, can identify these lineage-biased HSC subsets.
While the increased T-cell potential of cord blood HSC is
in accordance with the better reconstitution of early and
committed hematopoietic progenitors and the higher
thymic function and T-cell receptor diversity upon cord
blood HSC transplantation, in comparison with bone mar-
row HSC transplantation,30,31 it is unclear whether this is
due to the immaturity of the cord blood HSC, with a status
that more closely resembles that of embryonic stem cells, or
due to a difference in microenvironment at the time of iso-
lation. The former hypothesis is in line with our prelimi-
nary results that show that fetal liver- or fetal bone marrow-
derived HSC possess even higher T-cell potential compared
to cord blood HSC, while mobilized peripheral blood HSC
also show very little T-lineage capacity (data not shown). We,
therefore, favor the idea that precursors that are generated
earlier during ontogeny might possess a higher capability to
differentiate along the T-lineage pathway. This might be
the result of greater plasticity of fetal-derived progenitors
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Table 3. Influence of mixing bone marrow (BM) and cord blood (CB) HSC on differentiation.
Expt n°                                                            1                                                                                                                 2
Cell subset CD34+7- CD34+7+ CD34-7- CD34-7+ CD34+7- CD34+7+ CD34-7- CD34-7+
CB U 24.2 18.6 51.1 6.4 39.6 25.0 31.7 3.6
CB L 26.8 18.9 46.9 5.6 40.7 25.8 30.1 3.3
BM U 13.8 2.2 76.6 6.2 11.2 1.6 83.0 4.2
BM L 15.7 1.8 75.6 6.8 11.1 2.0 81.7 5.2
CB L+BM U 27.3 19.5 47.4 5.9 42.1 24.4 30.8 2.7
CB U+ BM L 16.7 2.2 75.7 5.5 11.3 2.4 81.1 5.2
The frequency of different subpopulations is shown. Comparative analysis of subpopulations generated from CB and BM HSC that are unlabeled (U) or labeled (L) with CFSE. The
CFSE-labeled populations are indicated in bold. In mixing experiments the frequency of the different subpopulations is given for the gated labeled cells. Experiments were performed
on OP9-DL1 cells as detailed in Figure 5.
than of their adult counterparts, resulting in more flexibility
to respond to specific environmental cues, such as Notch-
activating ligands. It will be of interest to investigate
whether this is caused by differences in the epigenetic land-
scape within the different HSC.
The present study has provided evidence to support the
hypothesis that human HSC are composed of heteroge-
neous cells wherein lymphoid-biased HSC are more
enriched in cord blood than in bone marrow. This bias can
be rapidly detected by monitoring changes in cell surface
proteins and as such, these findings could be of use for
exploring human markers, analogous to CD150 in the
mouse, which phenotypically discriminate between these
lineage-biased HSC. In any case, it will be essential to delin-
eate the molecular mechanisms that account for the defect
in early T-lineage differentiation of bone marrow-derived
HSC in order to improve immune reconstitution following
HSC transplantation.
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